Belomusodil is a new drug. We don’t have a lot of options for this population of chronic GVHD. So it was the first systematic review and meta-analysis of this drug. And we gathered more than 400 patients. And the drug showed an interesting overall response, the overall response rate was more than 50% and the tolerability was also good with less than 5% of patients discontinuing due to adverse events and the duration of response was also more than 50 weeks...
Belomusodil is a new drug. We don’t have a lot of options for this population of chronic GVHD. So it was the first systematic review and meta-analysis of this drug. And we gathered more than 400 patients. And the drug showed an interesting overall response, the overall response rate was more than 50% and the tolerability was also good with less than 5% of patients discontinuing due to adverse events and the duration of response was also more than 50 weeks. So it was a very interesting drug to use in this very pre-treated population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
